Provided by Tiger Trade Technology Pte. Ltd.

TransCode Therapeutics Inc.

5.47
+0.14002.63%
Post-market: 5.470.00000.00%19:37 EDT
Volume:38.31K
Turnover:206.90K
Market Cap:5.20M
PE:-0.11
High:6.00
Open:5.18
Low:5.02
Close:5.33
52wk High:20.99
52wk Low:3.82
Shares:950.30K
Float Shares:832.40K
Volume Ratio:1.37
T/O Rate:4.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-49.8904
EPS(LYR):-52.5900
ROE:-52.14%
ROA:-17.13%
PB:4.15
PE(LYR):-0.10

Loading ...

Company Profile

Company Name:
TransCode Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
12
Office Location:
6 Liberty Square,Suite 2382,Boston,Massachusetts,United States
Zip Code:
02109
Fax:
- -
Introduction:
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Directors

Name
Position
Philippe P. Calais
Chairman of the Board and Chief Executive Officer
Elizabeth Czerepak
Independent Director
Erik Manting
Independent Director
Jack Stover
Independent Director
Magda Marquet
Independent Director
Thomas A. Fitzgerald
Chief Financial Officer, Vice President and Director

Shareholders

Name
Position
Philippe P. Calais
Chairman of the Board and Chief Executive Officer
Thomas A. Fitzgerald
Chief Financial Officer, Vice President and Director